FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089615903> ?p ?o ?g. }

• W3089615903 endingPage "1695" @default.
• W3089615903 startingPage "1687" @default.
• W3089615903 abstract "Abstract Immunotherapy has revolutionized cancer treatment during the last years. Several monoclonal antibodies that are specific for regulatory checkpoint molecules, that is, immune checkpoint inhibitors (ICIs), have been approved and are currently in use for various types of cancer in different lines of treatment. Cancer immunotherapy aims for enhancing the immune response against cancer cells. Despite their high efficacy, ICIs are associated to a new spectrum of adverse events of autoimmune origin, often referred to as immune-related adverse events (irAEs), which limit the utility of these drugs. These irAEs are quite common and can affect almost every organ. The grade of toxicity varies from very mild to life-threatening. The pathophysiological mechanisms behind these events are not fully understood. In this review, we will summarize current evidence specifically regarding the rheumatic irAEs and we will focus on current and future treatment strategies. Treatment guidelines largely support the use of glucocorticoids as first-line therapy, when symptomatic therapy is not efficient, and for more persistent and/or moderate/severe degree of inflammation. Targeted therapies are higher up in the treatment pyramid, after inadequate response to glucocorticoids and conventional, broad immunosuppressive agents, and for severe forms of irAEs. However, preclinical data provide evidence that raise concerns regarding the potential risk of impaired antitumoral effect. This potential risk of glucocorticoids, together with the high efficacy and potential synergistic effect of newer, targeted immunomodulation, such as tumor necrosis factor and interleukin-6 blockade, could support a paradigm shift, where more targeted treatments are considered earlier in the treatment sequence." @default.
• W3089615903 created "2020-10-08" @default.
• W3089615903 creator A5000798254 @default.
• W3089615903 creator A5037276492 @default.
• W3089615903 creator A5050642371 @default.
• W3089615903 creator A5066518344 @default.
• W3089615903 creator A5090209554 @default.
• W3089615903 date "2020-09-28" @default.
• W3089615903 modified "2023-10-16" @default.
• W3089615903 title "Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?" @default.
• W3089615903 cites W1895277992 @default.
• W3089615903 cites W2002250199 @default.
• W3089615903 cites W2029275361 @default.
• W3089615903 cites W2035505806 @default.
• W3089615903 cites W2036320072 @default.
• W3089615903 cites W2046776183 @default.
• W3089615903 cites W2063485775 @default.
• W3089615903 cites W2078844752 @default.
• W3089615903 cites W2094991897 @default.
• W3089615903 cites W2104347254 @default.
• W3089615903 cites W2111913995 @default.
• W3089615903 cites W2113398090 @default.
• W3089615903 cites W2119896120 @default.
• W3089615903 cites W2125212735 @default.
• W3089615903 cites W2125988127 @default.
• W3089615903 cites W2130822830 @default.
• W3089615903 cites W2140111836 @default.
• W3089615903 cites W2140460887 @default.
• W3089615903 cites W2150857908 @default.
• W3089615903 cites W2150952126 @default.
• W3089615903 cites W2155464214 @default.
• W3089615903 cites W2162856391 @default.
• W3089615903 cites W2263759961 @default.
• W3089615903 cites W2280154361 @default.
• W3089615903 cites W2313175236 @default.
• W3089615903 cites W2345568581 @default.
• W3089615903 cites W2441690768 @default.
• W3089615903 cites W2527905628 @default.
• W3089615903 cites W2567564314 @default.
• W3089615903 cites W2572174216 @default.
• W3089615903 cites W2586424458 @default.
• W3089615903 cites W2736166064 @default.
• W3089615903 cites W2747028021 @default.
• W3089615903 cites W2766023480 @default.
• W3089615903 cites W2768429453 @default.
• W3089615903 cites W2771433910 @default.
• W3089615903 cites W2779658193 @default.
• W3089615903 cites W2783137027 @default.
• W3089615903 cites W2786816161 @default.
• W3089615903 cites W2792588868 @default.
• W3089615903 cites W2794163856 @default.
• W3089615903 cites W2811001941 @default.
• W3089615903 cites W2888599070 @default.
• W3089615903 cites W2888695906 @default.
• W3089615903 cites W2889317689 @default.
• W3089615903 cites W2890602826 @default.
• W3089615903 cites W2897516580 @default.
• W3089615903 cites W2901341811 @default.
• W3089615903 cites W2908586015 @default.
• W3089615903 cites W2943218134 @default.
• W3089615903 cites W2950056455 @default.
• W3089615903 cites W2950986625 @default.
• W3089615903 cites W2951418942 @default.
• W3089615903 cites W2952666958 @default.
• W3089615903 cites W2969985260 @default.
• W3089615903 cites W2972373703 @default.
• W3089615903 cites W2974173963 @default.
• W3089615903 cites W2975736685 @default.
• W3089615903 cites W2988124258 @default.
• W3089615903 cites W2997329361 @default.
• W3089615903 cites W3010839046 @default.
• W3089615903 cites W3015154527 @default.
• W3089615903 cites W3018517995 @default.
• W3089615903 cites W3023745224 @default.
• W3089615903 doi "https://doi.org/10.1007/s10067-020-05420-w" @default.
• W3089615903 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8102438" @default.
• W3089615903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32989505" @default.
• W3089615903 hasPublicationYear "2020" @default.
• W3089615903 type Work @default.
• W3089615903 sameAs 3089615903 @default.
• W3089615903 citedByCount "13" @default.
• W3089615903 countsByYear W30896159032021 @default.
• W3089615903 countsByYear W30896159032022 @default.
• W3089615903 countsByYear W30896159032023 @default.
• W3089615903 crossrefType "journal-article" @default.
• W3089615903 hasAuthorship W3089615903A5000798254 @default.
• W3089615903 hasAuthorship W3089615903A5037276492 @default.
• W3089615903 hasAuthorship W3089615903A5050642371 @default.
• W3089615903 hasAuthorship W3089615903A5066518344 @default.
• W3089615903 hasAuthorship W3089615903A5090209554 @default.
• W3089615903 hasBestOaLocation W30896159031 @default.
• W3089615903 hasConcept C121608353 @default.
• W3089615903 hasConcept C126322002 @default.
• W3089615903 hasConcept C143998085 @default.
• W3089615903 hasConcept C197934379 @default.
• W3089615903 hasConcept C203014093 @default.
• W3089615903 hasConcept C2777701055 @default.
• W3089615903 hasConcept C2780674031 @default.

• next